Mark Kiel

Executive Officer, Director at Genomenon.

Raised on Genomenon filings

$6M

of $10M offered across 1 Form D filing

Form D filings: 1
Teammates: 6
Last filing: Jul 30, 2026

Company

Biotech · Ann Arbor, MI

Curated literature evidence for interpreting gene variants

Curated literature evidence for interpreting gene variants

Investors: 30
Still open: $4M

Investors: 30
Sector: Biotech
HQ: Ann Arbor, MI

Genomenon filings

Genomenon Form D filings
Filed	Security	Sold of offered	Filing
Jul 30, 2026	Equity	$6M/ $10M	Form D

EquityFiled Jul 30, 2026Form D
$6M/ $10M

Works with

Also named on Genomenon filings

Brian GroarkChief Financial Officer, Form D signerForm D signer Sam GlobusExecutive Officer David GregorkaDirector Michael GrossDirector Michael KleinExecutive Officer, Director Patricia GlazaDirector